Skip to content
FDAMedicines

Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

FDA recall n-par-health-issues-voluntary-nationwide-recall-argatroban-injection-due-presence- ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel
Text from FDA, unedited.

The recalled product

Codes in the record. Click one to copy it.

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terepht
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots.

Administration of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) found to contain particulate matter, has a reasonable probability of causing life-threatening adverse health consequences including pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or inflammation of the walls of veins, which may lead to clotting. To date, Par Health has not received any reports of adverse events related to this recall.

Argatroban Injection 250 mg/2.5 mL (100 mg/mL) is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention.

Recalled product can be identified as follows and by representative labels at bottom of this document:

These lots were distributed nationwide to wholesalers and hospitals between December 30, 2024, and May 5, 2026.

Par Health is providing written notification to wholesale and hospital accounts that have received the affected lots and is arranging for return of all existing inventory through Inmar, Inc. Wholesale distributors and hospital pharmacies that have the product being recalled should immediately discontinue use and stop distribution. If you have further distributed the recalled product, please notify your accounts or any additional locations which may have received the recalled product.

Questions regarding this recall can be directed to Inmar, Inc. at 1-855-648-7909 Monday through Friday between the hours of 9 a.m. and 5 p.m. ET or by email at rxrecalls@inmar.com .

For medical or technical product information or to report a product complaint or adverse event please call 1-800-828-9393 Monday through Thursday between the hours of 9 a.m. and 8 p.m. ET or Friday between 9 a.m. and 6 p.m. ET.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online : www.fda.gov/medwatch/report.htm

Regular Mail or Fax : Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Package Identification: See representative examples of vial labels from selected affected lots below:

Contacts Gena Holthaus, Senior Director, Corporate Brand and Communications media.relations@parhealth.com

*Par Pharmaceutical, Inc. and Endo USA, Inc. are predecessor companies to Par Health USA, LLC, the current distributor of the product.

Text from FDA (the company’s words), unedited.
  • Argatroban Injection 250 mg/2.5 mL (100 mg/mL), Distributed by: Par Pharmaceutical* or Endo USA*

    Lot or code
    NDC: 42023-182-01; Lot: 83449; Expiration Date: 10/2026
  • 82682

    Lot or code
    NDC: 11/2026
  • 86714

    Lot or code
    NDC: 02/2027
  • 87302

    Lot or code
    NDC: 02/2027
  • 87560

    Lot or code
    NDC: 02/2027
  • 87753

    Lot or code
    NDC: 03/2027
  • 88401

    Lot or code
    NDC: 03/2027
  • 88614

    Lot or code
    NDC: 04/2027
  • 88836

    Lot or code
    NDC: 04/2027
  • 90220

    Lot or code
    NDC: 05/2027
  • 91216

    Lot or code
    NDC: 06/2027
  • 91219

    Lot or code
    NDC: 06/2027
  • 92004

    Lot or code
    NDC: 07/2027
  • 92006

    Lot or code
    NDC: 07/2027
  • 92009

    Lot or code
    NDC: 08/2027
  • 92596

    Lot or code
    NDC: 08/2027
  • 92782

    Lot or code
    NDC: 08/2027
  • 93107

    Lot or code
    NDC: 08/2027
  • 93329

    Lot or code
    NDC: 08/2027
  • 93890

    Lot or code
    NDC: 09/2027
  • 42023-182-89

    Lot or code
    NDC: 84193; Lot: 10/2026
  • 92880

    Lot or code
    NDC: 08/2027

Source

Issued by
U.S. Food and Drug Administration
Firm
Par Health USA, LLC (other notices of this firm)

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Par Health USA, LLC, Medicine: Argatroban, Month: October 2026, Week 2026-W42. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on October 13, 2026.

Other notices of Par Health USA, LLC